SBIR/STTR Research Award
Non-invasive prenatal testing of sickle cell disease
Award amount
$224,227Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BillionToOne, Inc.
- Proposal award date
- 2018-09-20
- Contract end date
- 2019-08-31
- UEI
- Not reported
- Solicitation number
- PA17-302
- Topic code
- NHLBI
Research abstract
Overinfants are born with sickle cell diseaseSCDevery year world wideincluding at leastin the USPrenatal diagnosis by amniocentesis or chorionic villus sampling is availablebut high costinvasivenessand risk of miscarriage limit their useThis Phase I SBIR project will show feasibility of a noninvasive test for Sickle Cell Disease that is affordable and completely safe to useBy finding their child s SCD
status before birthparents can opt for umbilical cord blood banking to save their child s stem cellsThese stem
cells could be critical for access to future gene therapy SCD cures that are in clinical trials and will likely become
approved in the nextyearsOur non invasive prenatal test uses the cell free DNA that a developing fetus sheds into the mother s
bloodstreamBy taking peripheral blood sample from a pregnant womanour assay is able to determine the fetal
genotype for sickle cell disease causing mutationsTo support this assaywe have developed innovative probes
for sickle cell alleles that can measure allele fractions with coefficient of variation andltthrough the use of nextgeneration DNA sequencingThis project will demonstrate the feasibility of our approach for non invasive prenatal testing of sickle
cell disease through the following specific aimsSpecific AimValidate optimized probes for HBB on cfDNA
isolated from healthy SCT individualsSpecific AimIdentify the fetal HBB genotypee gHbASHbSCor
HbSSfrom pregnant women who have SCDAimIdentify the fetal SCD genotypee gHbAAHbASHbSCor HbSSof pregnant women who have SCT This proposal aims to develop a non invasive prenatal test for sickle cell diseasewhich is the
most common genetically inherited disorder in the worldPrenatal testing for sickle cell disease
supports gene therapy cures by identifying when umbilical cord blood banking should be
performedThis Phase I SBIR will demonstrate the feasibility of non invasive prenatal testing for
sickle cell disease by performing the test on patients at high risk for having an affected child
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications